Search - tctmd.com

Displaying 261 - 269 of 269

Sort: Relevancy | Date

News Daily News

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Yael L. Maxwell

July 10, 2015

News Daily News

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

Yael L. Maxwell

July 10, 2015

News Daily News

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

June 25, 2015

News Industry News

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

June 25, 2015

News Daily News

Despite No Measurable Gain in QoL, Women Still Prefer Radial for Cardiac Cath

Caitlin E. Cox

May 15, 2015

News Daily News

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Todd Neale

January 28, 2015

News Conference News ESC 2012

Study Looks at Global Mortality, Stroke Rates in A-fib Patients After ER Visit

Yael L. Maxwell

August 29, 2012

News Daily News

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Caitlin E. Cox

July 12, 2012

News Daily News

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

L.A. McKeown

June 03, 2011

Advertisement

La Terapia Puente para Pacientes con FA No Previene los Tromboembolismos y Aumenta las Hemorragias

Bridging Therapy for A-fib Patients Fails to Prevent Thromboembolism, Increases Bleeding

RE-VERSE AD: Dabigatran Antidote Appears Safe, Effective in Interim Analysis

Portola Pharmaceuticals Announces In Vivo Study Results Demonstrating Andexanet Alfa Significantly Reduced Bleeding and Reversed Anticoagulation Activity of Rivaroxaban While Four-Factor Prothrombin C

Despite No Measurable Gain in QoL, Women Still Prefer Radial for Cardiac Cath

HF Worsens Outcomes Following ACS, With No Benefit From Apixaban

Study Looks at Global Mortality, Stroke Rates in A-fib Patients After ER Visit

Apixaban Less Costly Than Aspirin for Stroke Prevention in A-Fib at 10 Years

Dabigatran Cost-Effective Only for A-Fib Patients at High Stroke Risk

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content